Reviva Pharmaceuticals Holdings, Inc.

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapies for diseases with significant unmet medical needs. The company's mission is to deliver better, safer, and more effective treatments that can profoundly impact patients' lives, particularly in the areas of central nervous system, inflammatory, and cardiometabolic diseases. Reviva Pharmaceuticals is headquartered in Cupertino, California, United States.

The company's pipeline features two primary drug candidates: brilaroxazine (RP5063) and RP1208. Brilaroxazine, the lead candidate, is in clinical development for multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder (ADHD), and behavioral and psychotic symptoms associated with Alzheimer's disease and Parkinson's disease psychosis. Additionally, brilaroxazine is being developed for respiratory conditions such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis, and is in preclinical stages for psoriasis. RP1208 is under development for depression and obesity. Reviva leverages a chemical genomics-driven technology platform and proprietary chemistry in its drug discovery and development processes.

In March 2026, Reviva Pharmaceuticals Holdings Inc. announced the pricing of a public offering aimed at raising approximately $10 million, with the proceeds earmarked for research and development activities, including the planned RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia. This financing initiative followed a 1-for-20 reverse stock split that became effective earlier in March 2026. While the company reported positive data from its RECOVER Phase 3 clinical trial for schizophrenia in October 2023, meeting all primary and secondary endpoints, the FDA has recommended a second Phase 3 trial to gather additional efficacy and safety data before a New Drug Application (NDA) submission. The leadership team includes Dr. Laxminarayan Bhat, who serves as Founder, President, and Chief Executive Officer, and Narayan Prabhu, the Chief Financial Officer. As of late April 2026, Reviva Pharmaceuticals Holdings, Inc. maintained a market capitalization ranging from approximately $11.3 million to $12 million.